June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Rate of acute postoperative endophthalmitis after phacoemulsification using intracameral moxifloxacin
Author Affiliations & Notes
  • Justin Riffel
    University of Kansas Medical Center, Kansas City, Kansas, United States
  • Anjulie Quick
    University of Kansas Medical Center, Kansas City, Kansas, United States
  • Footnotes
    Commercial Relationships   Justin Riffel, None; Anjulie Quick, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 586. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Justin Riffel, Anjulie Quick; Rate of acute postoperative endophthalmitis after phacoemulsification using intracameral moxifloxacin. Invest. Ophthalmol. Vis. Sci. 2021;62(8):586.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ophthalmologists are increasingly utilizing intracameral (IC) antibiotics for prophylaxis during cataract surgery. We performed a retrospective chart review to evaluate the rate of acute postoperative endophthalmitis (POE) after cataract surgery using IC moxifloxacin at a tertiary academic center.

Methods : International Review Board approval was obtained from the University of Kansas Medical Center prior to the study. We conducted a retrospective chart review of phacoemulsification surgeries with or without intraocular lens placement. Surgeries were performed as either standalone procedures or in combination with other ophthalmic surgeries. The surgeries were performed by six cataract surgeons at a single institution between February 1, 2018 and August 10, 2020. All patients included in analysis received IC moxifloxacin during surgery. Patients who underwent combination surgeries received postoperative topical antibiotics in addition to IC moxifloxacin, while those who underwent standalone cataract surgery received IC moxifloxacin alone. Patients who did not receive IC moxifloxacin due to a preexisting fluoroquinolone allergy were excluded from analysis. Analysis included the rate of acute POE following all surgeries and the occurrence of any adverse reactions to IC moxifloxacin administration in those with a preexisting fluoroquinolone allergy.

Results : 2,359 eyes underwent cataract surgery (standalone and combination surgeries combined) over the study period. Zero cases of acute POE were observed after all 2,359 surgeries (0%). There were no reports of adverse reactions to IC moxifloxacin administration in the 43 patients identified as having a preexisting fluoroquinolone allergy (72 surgeries total), despite the most commonly listed preexisting allergic reaction to fluoroquinolones being “rash or itching.”

Conclusions : Our academic center’s rate of acute POE after cataract surgery using IC moxifloxacin is 0%. No adverse reactions to IC moxifloxacin administration were reported in patients with preexisting fluoroquinolone allergy. Importantly, no cases of acute POE were identified in patients who underwent standalone cataract surgery using IC moxifloxacin without the addition of postoperative topical antibiotics.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×